mAbxience opens $40M biosimilar antibody plant in Garín, Argentina

mAbxience, part of Insud Pharma, inaugurated a new biosimilar monoclonal antibody production plant in Garín, Buenos Aires, Argentina. The $40 million facility doubles the company's production capacity and created 50 new jobs.

“mAbxience inauguró una nueva planta de producción de anticuerpos monoclonales biosimilares en Garín, provincia de Buenos Aires (Argentina).”insudpharma.com

• 1 source
• insudpharma.commAbxience inaugura una nueva planta de anticuerpos monoclonales biosimilares en Argentina - Insud PharmaInsudPharmaFeb 21, 2020

Summarized from public sources; check the original articles before acting on it.